Edgewise Therapeutics Capital Surpluse Over Time
| EWTX Stock | USD 31.98 0.22 0.68% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Edgewise Therapeutics Performance and Edgewise Therapeutics Correlation. Edgewise |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edgewise Therapeutics. If investors know Edgewise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edgewise Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Return On Assets (0.22) | Return On Equity (0.32) |
The market value of Edgewise Therapeutics is measured differently than its book value, which is the value of Edgewise that is recorded on the company's balance sheet. Investors also form their own opinion of Edgewise Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Edgewise Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edgewise Therapeutics' market value can be influenced by many factors that don't directly affect Edgewise Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edgewise Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edgewise Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edgewise Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capital Surpluse Analysis
Compare Edgewise Therapeutics and related stocks such as Century Therapeutics, C4 Therapeutics, and Mineralys Therapeutics, Capital Surpluse Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPSC | 785 M | 785 M | 785 M | 785 M | 785 M | 785 M | 785 M | 785 M | 785 M | 785 M | 785 M | 785 M | 824.3 M | 947.9 M | 885.1 M |
| CCCC | 464.6 M | 464.6 M | 464.6 M | 464.6 M | 464.6 M | 464.6 M | 464.6 M | 464.6 M | 464.6 M | 464.6 M | 464.6 M | 658.1 M | 689.3 M | 792.6 M | 664.4 M |
| CGEM | 584.7 M | 584.7 M | 584.7 M | 584.7 M | 584.7 M | 584.7 M | 584.7 M | 584.7 M | 584.7 M | 584.7 M | 584.7 M | 584.7 M | 585.3 M | 673.1 M | 643.5 M |
| VOR | 346.4 M | 346.4 M | 346.4 M | 346.4 M | 346.4 M | 346.4 M | 346.4 M | 346.4 M | 346.4 M | 346.4 M | 346.4 M | 346.4 M | 473.6 M | 544.6 M | 451 M |
| IKNA | 353.3 M | 353.3 M | 353.3 M | 353.3 M | 353.3 M | 353.3 M | 353.3 M | 353.3 M | 353.3 M | 353.3 M | 353.3 M | 353.3 M | 361.9 M | 416.2 M | 393.4 M |
| DSGN | 429.8 M | 429.8 M | 429.8 M | 429.8 M | 429.8 M | 429.8 M | 429.8 M | 429.8 M | 429.8 M | 429.8 M | 429.8 M | 429.8 M | 441.4 M | 507.6 M | 479.2 M |
| XLO | 346.3 M | 346.3 M | 346.3 M | 346.3 M | 346.3 M | 346.3 M | 346.3 M | 346.3 M | 346.3 M | 346.3 M | 346.3 M | 346.3 M | 354.8 M | 408 M | 385.6 M |
| HOWL | 405.7 M | 405.7 M | 405.7 M | 405.7 M | 405.7 M | 405.7 M | 405.7 M | 405.7 M | 405.7 M | 405.7 M | 405.7 M | 405.7 M | 429 M | 493.4 M | 459.1 M |
| CELC | 10 M | 10 M | 10 M | 10 M | 10 M | 10 M | 13.9 M | 33.4 M | 34.8 M | 36.1 M | 38 M | 124.6 M | 230 M | 264.6 M | 277.8 M |
| RVMD | 216 K | 216 K | 216 K | 216 K | 216 K | 216 K | 216 K | 216 K | 1.3 M | 4.7 M | 740.1 M | 1.1 B | 1.1 B | 1.2 B | 1.3 B |
| BDTX | 105 K | 105 K | 105 K | 105 K | 105 K | 105 K | 105 K | 105 K | 169 K | 3.8 M | 425.4 M | 440.1 M | 452.5 M | 520.4 M | 546.4 M |
| PASG | 475.6 M | 475.6 M | 475.6 M | 475.6 M | 475.6 M | 475.6 M | 475.6 M | 475.6 M | 475.6 M | 475.6 M | 475.6 M | 675.3 M | 694.7 M | 798.9 M | 676.8 M |
Edgewise Therapeutics and related stocks such as Century Therapeutics, C4 Therapeutics, and Mineralys Therapeutics, Capital Surpluse description
My Equities
My Current Equities and Potential Positions
| Edgewise Therapeutics | EWTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 31.98
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.